| 释义 |
filgrastim, n. Pharmacol.
Brit. |fɪlˈgrastɪm|, U.S. |fɪlˈgræstɪm|
[‹ fil- (perhaps representing -phil in neutrophil adj. and n.) + -gra- (in granulocyte n.) + -stim (in stimulating adj.): compare granulocyte colony-stimulating factor n. at granulocyte n. Additions]
A form of human granulocyte colony-stimulating factor produced by recombinant DNA technology, used chiefly for the treatment of chemotherapy-induced neutropenia; also called Neupogen.
Filgrastim is a non-glycosylated protein containing an added N-terminal methionine residue.
1991Drug Topics 8 Apr. 22/1 Recombinant G-CSF (filgrastim), aimed at decreasing the frequency and severity of chemotherapy-induced neutropenia, was approved in February. 1997Denver Post (Nexis) 4 Feb. b2 As a result, [HIV-infected] patients treated with Filgrastim had 45 percent fewer hospital days for bacterial infection over the 24-week study period. 2001N.Y. Rev. Bks. 11 Jan. 46/2 Neupogen, a registered trademark of filgrastim, a granulocyte-colony-stimulating recombinant DNA drug. |